982 related articles for article (PubMed ID: 19302272)
1. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.
Billaud EM; Guillemain R; Berge M; Amrein C; Lefeuvre S; Louët AL; Boussaud V; Chevalier P
Med Mycol; 2010 Nov; 48 Suppl 1():S52-9. PubMed ID: 21067331
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
8. [Level of evidence for therapeutic drug monitoring of voriconazole].
Hulin A; Dailly E; Le Guellec C;
Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
[TBL] [Abstract][Full Text] [Related]
9. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
10. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
13. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring.
Eiden C; Cociglio M; Hillaire-Buys D; Eymard-Duvernay S; Ceballos P; Fegueux N; Peyrière H
Xenobiotica; 2010 Oct; 40(10):701-6. PubMed ID: 20642349
[TBL] [Abstract][Full Text] [Related]
16. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
18. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis.
Berge M; Chevalier P; Benammar M; Guillemain R; Amrein C; Lefeuvre S; Boussaud V; Billaud EM
Ther Drug Monit; 2009 Jun; 31(3):396-9. PubMed ID: 19349930
[TBL] [Abstract][Full Text] [Related]
19. Dose tolerability of chronically inhaled voriconazole solution in rodents.
Tolman JA; Nelson NA; Bosselmann S; Peters JI; Coalson JJ; Wiederhold NP; Williams RO
Int J Pharm; 2009 Sep; 379(1):25-31. PubMed ID: 19524030
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]